Stereotactic Body Radiation Therapy in the Management of Oligometastatic Uterine Cancer

Abstract

Introduction: Limited data exist for the use of stereotactic body radiotherapy (SBRT) in oligometastatic uterine cancer. We aimed to evaluate the outcomes of using SBRT for treating oligometastatic uterine cancer.

Methods: This is a single-institute retrospective study evaluating the use of SBRT in patients with oligometastatic uterine cancer. Survival Endpoints were analyzed using the Kaplan-Meier method.

Results: Twenty-three uterine cancer cases with 24 oligometastatic sites were identified, who received SBRT to metastatic sites between 2011 and 2022. The median follow-up period was 30 months (IQR 14-63). The median SBRT dose, fractions, and BED10 were 42 Gy (IQR: 35-45), 5 fx (IQR: 5-5), and 77 Gy (IQR: 60-86). The median time for reirradiation was 30 months (IQR 14-81). Nodal recurrences in 58% of cases were the most common site for SBRT use. The 6-month, 1-, and 2-year local control was 87%, 83%, and 77%, and locoregional control was 83%, 69%, and 64%, respectively. Acute toxicities were observed in 50% of cases with 42% of grade 1 fatigue. Late toxicities were observed in two cases (8%) of grade 2 bowel toxicity. No grade 3 or higher toxicity.

Conclusion: SBRT is a safe and effective tool for the management of oligometastatic uterine cancer.

Keywords: Oligometastatic; SBRT; Uterine cancer.